Recuro Health, recognized by Newsweek and Statista as one of the “World’s Best Digital Health Companies 2024,” stands out for its comprehensive virtual care solutions—including primary care, urgent care, behavioral health, genomics, and at-home diagnostics—underscoring its role as a telehealth leader
The inaugural Newsweek ranking assessed 400 digital health companies across 35 countries in sectors such as diagnostics, health records, medical management, and telehealth. Recuro’s inclusion reflects strong performance in technology, impact, and patient accessibility
Phil Fasano, CEO and Chairman of Recuro, shared:
“We are honored to be recognized among the world’s top digital health companies by Newsweek… a testament to our relentless dedication to delivering innovative and accessible healthcare solutions that improve patient outcomes
Dr. Kate Sowerwine, Chief Medical Officer, added that Recuro’s “Complete Care all‑in‑one solution”—integrating genomic testing, at‑home labs, and health risk assessments—improves outcomes and reduces costs for employers and patients alike
Shortly after, Becker’s Hospital Review named Recuro among the Top 10 companies in at-home care, citing its integrated virtual primary, behavioral, and urgent care offerings
Recuro’s virtual-first care platform delivers holistic, personalized healthcare—24/7 access to primary, urgent, and behavioral care, supplemented with lab and genomic testing—supporting proactive and coordinated patient care
This recognition underscores Recuro’s commitment to reducing care barriers, enhancing patient outcomes, and driving cost efficiency through advanced virtual care services. It also reinforces its strategic vision to redefine how healthcare is accessed and delivered
New venture capital firm to create and invest in early-stage healthcare companies applying novel technologies to frontier biology and redefine patient care
Radiopharmaceuticals are emerging as the future of cancer care, combining targeted precision with powerful radiation to deliver safer, more effective treatments.
Join us in building the future of medicine through innovative technology and biology convergence
